American Journal of Medical Case Reports
ISSN (Print): 2374-2151 ISSN (Online): 2374-216X Website: http://www.sciepub.com/journal/ajmcr Editor-in-chief: Apply for this position
Open Access
Journal Browser
Go
American Journal of Medical Case Reports. 2021, 9(3), 170-171
DOI: 10.12691/ajmcr-9-3-10
Open AccessLetter To Editor

Remdesivir induced Liver Injury in a Patient with Coronavirus Disease 2019

Mohamedanwar Ghandour1, , Samah Suleiman1, Yahya Osman-Malik2 and Zeenat Y. Bhat2

1Department of Internal Medicine, Nephrology division, Wayne State University/Detroit medical Center, Michigan, USA

2Department of Internal Medicine WSU SOM, Division of Nephrology Wayne State University, Michigan, USA

Pub. Date: January 13, 2021

Cite this paper:
Mohamedanwar Ghandour, Samah Suleiman, Yahya Osman-Malik and Zeenat Y. Bhat. Remdesivir induced Liver Injury in a Patient with Coronavirus Disease 2019. American Journal of Medical Case Reports. 2021; 9(3):170-171. doi: 10.12691/ajmcr-9-3-10

Abstract

Remdesivir, is a broad-spectrum antiviral medication that has been used recently for COVID-19 patients. Herein, we report a case of COVID-19 who developed liver injury following administration of remdesivir.

Keywords:
COVID-19 liver injury

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]  Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19-preliminary report [manuscript published online ahead of print 22 May 2020]. N Engl J Med 2020.
 
[2]  Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30(3): 269-271.
 
[3]  Williamson BN, Feldmann F, Schwarz B, et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Nature. 2020.
 
[4]  Remdesivir (VEKLURY) [package insert]. Food and Drug Administration. 2020. Available at:https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214 787Orig1s000lbl.df. Accessed: October 25, 2020.
 
[5]  Gilead. Summary on compassionate use. Available at: https://www.ema.europa.eu/en/documents/other/summary- compassionate-use-remdesivir-gilead_ en.pdf. Accessed 4 June 2020.
 
[6]  Mulangu S, Dodd LE, Davey RT Jr, et al; PALM Writing Group; PALM Consortium Study Team. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med 2019; 381: 2293-303.
 
[7]  Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 days in patients with severe Covid-19 [manuscript published online ahead of print 27 May 2020]. N Engl J Med 2020.